90y basiliximab

From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

90y basiliximab - a radioimmunoconjugate composed of basiliximab, a chimeric, mouse human monoclonal antibody directed against the alpha subunit of interleukin 2 receptor (il 2r alpha, cd25 or tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium y 90 basiliximab selectively binds to il 2r alpha expressed on the surface of activated t lymphocytes, thereby preventing il 2 binding and blocking the il 2 mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the il 2 receptor. This may prevent t cell mediated activation of the immune system against a certain transplant and may prevent transplant rejection.

Up to date info

UpToDate

Latest research - 90y basiliximab

PubMed
Clinical trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 90y basiliximab for any updates.

 

90y basiliximab is part of WikiMD's free ^articles!

^90y basiliximab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available